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Until quite recently it was possible to give only highly tentative opinions 
on the role of liver transplantation in the treatment of patients dying of incur-
able liver disease. Now, a much more authoritative position concerning clinical 
liver transplantation can be taken, since there have been six patients who have 
lived for more than a year after removal of their own diseased livers and 
replacement with cadaveric organs. 
The mortality has been high, just as it was in the first trials with renal 
transplantation. Nevertheless, we believe that the future role of liver transplan-
tation in hepatic disease will not be fundamentally different than cadaveric 
kidney transplantation in the field of renal disease. In this paper we will give 
the justification for this optimistic view, mention the indications for such oper-
ations as they have become clear in the last year and, above all, focus atten-
tion upon the errors in technique or judgment we have made which have 
accounted for most of the early deaths in our experience. 
INDICATIONS 
Nonneoplastic Disease 
Liver transplantation at the present time is indicated only for patients with 
severe and otherwise untreatable liver disease. A common indication is congen-
ital biliary atresia, when the abnormality cannot be corrected by conventional 
surgical techniques. End-stage cirrhosis of the liver also provides a large pool 
of potential candidates for transplantation. 
It is almost certain that a variety of inborn errors of metabolism could be 
cured by liver transplantation, since it has already been established that a 
number of proteins with identifiable phenotypes are changed after orthotopic 
liver transplantation to types previously present in the donor. 
The role of liver transplantation for the treatment (If acute hepatic disease 
caused by viruses or drugs has not been adequately evaluated. In such cases, 
two major handicaps are the fulminating nature of the hepatic failure and the 
possibility that the agents responsible for the original hepatic injury couId also 
adversely affect the homograft. 
* Supported by United States Public Health Service grants AM-06344, AM-07772, 
FR-00051, AI-04152, FR-00069, AM-12148, and AI-AM-08898. 
251 
252 Annals New York Academy of Sciences 
Neoplastic Disease 
It was once thought that a prime indication for liver replacement would be 
malignant hepatoma. As will be mentioned later, this expectation has not been 
fulfilled since we have invariably encountered recurrent neoplasm in our expe-
rience despite what was thought to be complete excision of the primary tumors 
at the time of total hepatectomy and liver replacement. 
AUXILIARY LIVER TRANSPLANTATION 
In this kind of liver transplantation, the host's diseased organ is not 
removed but a second liver is placed in some ectopic location such as the right 
paravertebral gutter, pelvis, or splenic fossa. At first thought this kind of oper-
ation has a special appeal, since it does not involve sacrificing whatever resid-
ual function may be left in the host's own liver. However, no patient so 
treated has been rehabilitated, and the maximum survival in any such opera-
tion has been only 35 days. 
There are serious disadvantages to auxiliary liver transplantation. First, 
such homografts ideally should receive a double blood supply, the venous com-
ponent coming from the splanchnic bed, a condition that from a technical 
point of view may be extremely difficult to realize in humans. Secondly, a kind 
of physiologic competition may exist between the homograft and the host's 
own liver even though the autologous organ is diseased. In dogs, this compe-
tion can easily be shown to cause atrophy of the transplant. In clinical cases 
the role of interliver competition is not known, although there is some evi-
dence that it may be a factor.l 
There is another disadvantage of auxiliary transplantation. Victims of ter-
minal liver disease are unusually prone to all kinds of infectious complications, 
especially those involving the lungs. The placement of an extra organ in the 
abdominal cavity of such recipients has not been well tolerated in respect to 
respiratory physiology. Throughout the world reports have come in, with 
deadly consistency, of these patients developing lethal pneumonitis. 
ORTHOTOPIC LIVER TRANSPLANTATION 
Those clinical successes mentioned in the inttoduction have all been with 
orthotopic transplantation. In this operation a place is made for the new organ 
by removal of the diseased liver. In principle the procedure could hardly be 
more simple, since it involves the restoration of normal vascular channels plus 
provision for biliary drainage, usually with a cholecystoduodenostomy. In prac-
tice, however, the operation may be difficult because of the extremely poor 
condition of most prospective recipients, because severe portal hypertension 
must usually be dealt with, and perhaps most importantly because of a high 
incidence of anatomic anomalies which are encountered. 
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Anatomic Anomalies 
Vascular 
The most common vascular anomaly is that found when the arterial supply 
comes both from the celiac axis and the superior mesenteric artery. Some vari-
ation from normal can be expected in about 20% of livers. Since the anom-
aly may occur in either the donor or the recipient, it is necessary to perform a 
modified procedure in almost 40% of human cases. 
When double arteries are encountered in the donor liver, they can either be 
anastomosed directly to the right and left hepatic arteries of the recipient, or a 
segment of the donor aorta in continuity with the origins of hepatic arteries 
can be sewn to the host aorta. When the double arteries are encountered in the 
recipient, they are often of small size and it may be preferable to ligate them. 
In that case, a Carrel patch of the donor aorta bearing the celiac axis and its 
hepatic branch can be sewn into the anterior wall of the recipient aorta. 
In one of the two cases in which this was done a large caudate lobe of the 
liver caused compression of the arterial supply, leading to prompt death of the 
patient. In the second case this also occurred, but the problem was recognized 
on the operating table and the donor celiac axis was then anastomosed to the 
host's right hepatic artery. However, the patient died 12 hours later of portal 
vein thrombosis. This was probably caused by a gross disparity in size between 
the donor and recipient veins, the vessel in the host being hypoplastic. 
Biliary Tract 
Anomalies of the bile ducts may also contribute to the hazards of the oper-
ation. In three patients, the cystic duct ran parallel to or behind the common 
bile duct for some distance before finally entering it. In one patient the prob-
lem was not recognized during donor hepatectomy, and a ligature was inad-
vertently placed around both structures causing obstruction proximal to the 
cholecystoduodenostomy. The patient developed progressive jaundice and died. 
In the other two patients the anomaly was recognized, the gallbladder was 
removed, and choledocho-choledochostomy was performed. However, the re-
cipients died of upper abdominal sepsis. 
Ischemic Injury of the Liver 
We have described only a partial list of the technical problems that have 
been directly responsible for failure. Another kind of combined technical and 
judgment error is the use of an organ that has been irreparably damaged by 
ischemia in the donor. After operation, evidence of very serious ischemic 
injury is manifested by an early rise in the transaminase values, deepening 
jaundice, and deterioration of other liver functions. The use of such badly 
damaged organs has essentially been eliminated in most centers by clarification 
of the criteria of brain death that have made it possible to remove organs at 
an earlier time. 
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Preservation of Donor Liver 
There have been other innovations which have made it possible to assure 
good quality liver homografts. After death, circulation to the liver can be 
maintained while it is being dissected free by simply using a standard cardi-
opulmonary bypass. In addition, a heat exchanger is used in the circuit to pro-
vide hypothermia of the perfused liver. After excision of the liver, it can be 
transplanted immediately or placed in a conservation chamber employing low-
flow perfusion, hyperbaric oxygenation, and hypothermia. Using the latter 
method, the organ can be kept in good condition for as long as eight hours. 
Rejection 
Apart from technical risks, the main threat to the liver is rejection by the 
host. This may take one of several forms. One variety is subclinical rejection, 
in which there is only biochemical evidence of deterioration of function of the 
transplanted liver after an initial period of satisfactory performance. The bili-
rubin level does not rise, but there are definite increases in the serum transami-
nases and the alkaline phosphatase. In most cases, these eventually return to 
normal. A very common finding at the time of hepatic homograft rejection is 
swelling of the homograft, as can be demonstrated by serial liver scans. 
A second form of rejection is of a rather indolent nature. Jaundice devel-
ops slowly and insidiously over a period of many weeks. The elevated bilirubin 
level is accompanied by elevation of the alkaline phosphatase. With prolonged 
steroid therapy, the immunologic process can eventually be reversed. 
On several occasions, a third variety of rejection has presented as a crisis. 
In these cases the patients have often become violently ill, since jaundice has 
developed with amazing rapidity. In one patient, the bilirubin rose from almost 
normal levels to 15 mg% in little more than one day. At the peak of the 
rejection crisis a gram-negative septicemia may develop, indicating that the 
injured liver is unable to clear microorganisms reaching it from the bowel. 
In experimental animals, it has been shown that liver rejection is invariably 
accompanied by a sharp decline in the total hepatic blood flow. Serial liver 
scans in patients may reveal changes which are probably due to similar immu-
nologically mediated falls in blood flow. As the rejection crisis develops, large 
areas of the liver cease to take up the technetium isotope. However, with relief 
of the rejection, the poorly opacified portion of the liver regains its reticuloen-
dothelial function and the scan appearance improves. 
It is probable that the chain of events just described occurred in five of 
the first patients who achieved extended survival after liver transplantation to 
such a severe degree that frank necrosis of the liver resulted. Associated with 
the appearance of large filling defects in the liver scans, the patients became 
prostrated, developed a gram-negative septicemia, and at reoperation had 
regional necrosis of their homo grafts which tended to be localized to the right 
lobe. The septicemia apparently resulted from the devitalized hepatic tissue 
being invaded by bacteria that are normally present in the intestine. The 
microorganisms were then disseminated from the focus of gangrene. 
A mechanical factor probably contributed to the localization of the hepatic 
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infarctions to the right lobe in these early cases. This was shown by perform-
ing simulated liver transplants in recently deceased cadavers. The suspensory 
ligaments of the liver were incised and a choledochoduodenostomy was con-
structed. The liver was then able to rotate slightly and cause minor kinking of 
the right hepatic artery. However, the primary factor in causing the hepatic 
infarctions even in these patients probably was low-grade rejection which, in 
turn, was due to inadequate immunosuppression. Thus, paradoxically, the way 
to avoid this complication of hepatic sepsis is to give heavy immunosup-
pression in the early postoperative period. 
A fourth variety of rejection is a chronic form which starts late after trans-
plantation and usually proves to be nonreversible. It is manifested by a clini-
cal picture resembling obstructive jaundice, with elevation of the bilirubin and 
alkaline phosphatase levels. Despite this, the patients may remain surprisingly 
well with retention of good synthetic function in the liver for many months or 
even years. Alternatively, there may be a slow progressive decline in liver 
function that may necessitate retransplantation as was done in one of our 
patients 12lh months after an initial transplantation for a hepatoma. 
Long-Term Results 
It has become clear to us that efforts to treat hepatic malignancy with liver 
replacement are not going to be very fruitful. To date, we have had five 
patients with hepatoma who have lived long enough following operation to 
permit meaningful observations about the natural history of this disease after 
what was thought to be complete excision of the neoplasm. Recurrent tumor 
developed in all five cases. One of the patients died of other causes after 2Y:z 
months although there were already pulmonary metastases. The other four 
were killed by their malignancies after 5, 12, 13, and 14lh months. The hom-
ograft itself became the seat of metastases in four of the cases, and was largely 
replaced by tumor in two of these. 
There is a great deal of evidence that immunosuppressive agents may 
actually increase the growth rate of malignant cells. Consequently, if hepato-
mas are to be treated with transplantation, stringent precautions must be taken 
to be sure that no tumor is left behind. 
To date we have treated three patients for benign disease (biliary atresia), 
with survival for more than a year. One of these recipients died of hepatic 
insufficiency after 14 months. A second is in good condition after 20lh months, 
although he has imperfect liver function. The third patient was treated 15 
months ago, and has completely normal hepatic function today. 
There is now enough information to permit the construction of life survival 
curves in recipients of orthotopic liver homo grafts. FIGURE 1 summarizes our 
total experience from March 1963 until February 1969. There were 25 consec-
utive cases. The first seven attempts resulted in death of the recipient within 
23 days or less. The first patient who achieved extended survival was operated 
upon in July 1967. Of the remaining patients treated, those still living now 
have a minimum follow-up of 15 months so that the life survival curve is 
complete beyond one year. Six of these last eighteen patients lived for at least 
one year. This survival rate of 33 % is almost identical to that achieved in 
cadaveric renal transplantation when the first successful trials with that opera-
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FIGURE 1. Survival curve of 25 patients treated at our institutions with orthotopic 
liver transplantation between March 1963 and February 1969. The shortest follow-up 
for recipients who were still alive in June 1969 is 15 months. Thus the curves may 
be considered complete to one year. The results have also been divided ac-
cording to the first, second, and third intervals of our total experience. 
Hon were made from 1962-1964. The uncorrected one-year survival, including 
the first seven failures, was 24%. Thus, the results of liver transplantation are 
hardly discouraging, since all these patients would otherwise have been 
doomed to an early death. Moreover, we can be certain that by avoiding the 
pitfalls already mentioned, these statistics will be steadily improved, as has 
occurred with renal transplantation. 
SUMMARY 
Orthotopic liver transplantation, which proved to be a feasible undertaking 
in dogs more than five years ago, has become possible in humans. Six patients 
with liver replacement have now lived for more than a year; the maximum 
survival time so far has been 20 months in a patient who is still alive. The 
prime indication for liver transplantation is benign hepatic disease. Liver re-
placement for hepatoma has, in our experience, not prevented the development 
of metastases. It now seems certain that liver transplantation will achieve a 
legitimate and important place in the armamentarium available for the treat-
ment of severe liver disease. 
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DISCUSSION OF THE PAPER 
UNIDENTIFIED SPEAKER: Assuming we can find a way to get better tissue 
matches, I wonder if the liver may do better than some other organs in trans-
plantation. 
DR. PENN: We will not attempt to do a transplant of any organ without 
prior histocompatibility matching. In the case of transplants of organs between 
related living donors, as in kidney transplantation, we believe that histocompat-
ibility matching is a very useful guide. A good match in general means little 
rejection, whereas a bad match would indicate problems with rejection. How-
ever when we come to transplant organs from unrelated cadaver donors, we 
do not know what the significance of histocompatibility matching is. We have 
seen numerous cases where bad matches have given good results and good 
matches have led to poor results. In fact, many of our best results with liver 
transplantation have been in patients with bad matches, the so-called Terasaki 
C or D match. The one child I showed you, is a 15 months survivor with a D 
match involving a mismatch of three of the HLA antigens. So I'm afraid I 
don't know what the significance of histocompatibility matching is as regards 
cadaver organs. 
DR. LEE (Richmond, Va.): I would like to comment on the correlation 
with histocompatibilities. The difficulty here is, as he says, in understanding its 
significance. In cadaver transplant of kidneys, the correlation isn't as good as it 
is with living related siblings. The second point I would make is illustrated by 
one experience we had in a recent liver transplant attempt. We had a donor 
which matched very well, then cross-matched it to make sure that the recipient 
didn't have a serum antibody against the donor cells, using the peripheral lym-
phocyte, as we always do. Again this was negative. So we transplanted the 
liver and it worked well, the liver pinked up immediately and everyone was 
pleased. Within a few hours, however, the patient was doing poorly, and at 
reoperation, the liver was pale and blotchy. This is somewhat analogous with 
so-called hyperacute rejection in the kidney. We suspected thrombosis as a 
result of a mechanical problem, but actually at postmortem examination there 
was no thrombosis in the major arteries. We rechecked the matches and found 
that the donor's kidney cells and liver cells did indeed react with recipient's 
serum, which we couldn't do before transplant was completed. So it is not as 
simple as assuming that if tissue matching is good, the result will be good. 
DR. PENN: So far, we've avoided the problem that Dr. Lee mentions. 
DR. ZUIDEMA (Johns Hopkins University, Baltimore, Md.): Dr. Penn, 
would you care to comment on the pig liver transplants? I believe that several 
of these have been carried out without immunosuppression; would you com-
ment on that point. 
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DR. PENN: I think this is one of the most interesting aspects of transplan-
tation of the liver. This is work that's been done mainly by Dr. Roy CaIne in 
Cambridge, England, who has done transplants between unrelated pigs, and 
has demonstrated prolon~ed survival in some of the animals, even though there 
were histocompatibility barriers. Now what the exact explanation for this is, is 
not known, but he believes that it is possible that the liver may produce some 
substance which may affect the immune apparatus. 
We have had some similar results in dogs who were kept on immunosup-
pression for a period. The immunosuppression was then stopped; some of the 
animals died of rejection, but there were a few of the animals that have sur-
vived. We have two dogs that are now alive five years following liver trans-
plantation, who only had immunosuppression for the first four months follow-
ing the transplant. 
DR. DEUTSCH (Philadelphia, Pa.): Is there any relation in your animal 
work between the mass of liver tissue transplanted and the rejection? 
DR. PENN: Studies have been done about so-called antigenic overload. 
It appears that this is not of importance in liver transplantation. We've seen 
some frightful rejections with liver transplantation in man. 
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